サマリー

過活動膀胱治療の世界市場は、2022年の35億米ドルから2027年には42億米ドルに達すると予測され、予測期間中のCAGRは3.6%となります。世界中で過活動膀胱の有病率が上昇していることと、利用可能な治療オプションに関する認知度が高まっていることが、市場の成長を後押ししています。また、OABの治療に神経調節技術を使用することで、さらに大きなプラスの効果が期待されます。


"2021年、ミラベルゴンセグメントが過活動膀胱（OAB）治療市場を支配"

過活動膀胱治療市場は、タイプ別に、抗コリン剤、ミラベグロン、BOTOX、神経調節法、その他の治療法に分類されます。ミラベグロンは、市場で入手可能な他の薬物クラスと比較して、この薬物に関連する副作用が少ないことから、2021年の市場で圧倒的なシェアを占めています。さらに、神経調節分野は、OAB用の新しいSNMおよびPTNSの市場投入により、より速いペースで成長すると予想されます。

「特発性過活動膀胱は、予測期間中に過活動膀胱治療薬市場で最も高い成長を遂げると予想されます。

過活動膀胱治療市場は、疾患タイプに基づき、特発性過活動膀胱と神経原性過活動膀胱に区分されます。特発性過活動膀胱の市場は、特発性過活動膀胱の有病率の高さと治療薬の増加により、より大きなシェアを占めています。

"2021年は北米が圧倒的なシェアを占めた"
過活動膀胱（OAB）治療市場は、地域的には、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分されます。2021年、北米はOAB治療市場の主要シェアを占めています。北米は、この地域のOAB治療市場の成熟につながる主要な市場プレーヤーの大部分を保持しています。さらに、米国における有利な償還政策が、北米の市場成長を予測する主要な要因の1つとなっています。

本レポートで実施した主なインタビューは、以下のように分類されます。
- 企業タイプ別 - 供給側：80.0%、需要側：20.0
- 役職別 - マネージャー: 45.0%, CXO & ディレクター: 30.0%, エグゼクティブ: 25.0
- 地域別：北米55％、欧州20％、アジア太平洋10％、中南米10％、中近東・アフリカ5
報告書に掲載されている企業一覧
o アステラス製薬株式会社（日本）
o テバ・ファーマシューティカル・インダストリーズ（日本(イスラエル)
o ファイザー株式会社（米国）
o Abbvie Inc.(米国)
o Viatris Inc.（米国）
o 久光製薬株式会社 (日本)
o ジョンソン・エンド・ジョンソンサービス株式会社（米国）
o エンドー・ファーマシューティカルズ・インク (アイルランド)
o ルパン（インド）
アムニール・ファーマシューティカルズLLC（米国）
o Sun Pharmaceutical Industries Ltd.(インド)
o グレンマーク（インド）
o マクレオッズ・ファーマシューティカルズ・リミテッド（インド）
o メドトロニック（アイルランド）
o アジャンタ・ファーマ（インド）
o グラニュールス インディア リミテッド（インド）
o ウロバント・サイエンシズ（米国）
o アポテックス・インク（カナダ）
o レイボリー（米国）
o Intas Pharmaceuticals Ltd.(インド)
o バイエル薬品（ドイツ）
o メディトックス（韓国）
o アルサーックス・ファーマシューティカルズ（米国）
o 大鵬薬品工業株式会社（日本(日本)
o ヒュ-ゲル社（韓国）
調査対象範囲
本レポートは、世界の過活動膀胱治療市場の詳細図を提供します。タイプ、疾患タイプ、地域などの異なるセグメントにおける市場規模および今後の成長可能性を推定することを目的としています。また、市場成長に影響を与える要因（促進要因、阻害要因、機会など）を分析しています。利害関係者向けに市場の機会を評価し、市場リーダー向けに競争環境の詳細を提供しています。また、マイクロマーケットについて、その成長動向、展望、細胞分析市場全体への貢献度に関しても調査しています。本レポートでは、4つの主要地域に関して、市場セグメントの収益を予測しています。


レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供しています。
- 市場の浸透。細胞分析市場の上位25社が提供する細胞分析に関する包括的な情報。過活動膀胱治療市場をタイプ別、疾患タイプ別、地域別に分析したレポートです。

- 市場の発展。有利な新興市場に関する包括的な情報です。主要な地域ごとの各種細胞解析の市場を分析しています。

- 市場の多様化。過活動膀胱（OAB）治療市場における新製品、未開拓の地域、最近の開発、投資に関する徹底的な情報を提供します。

- 競争力の評価。過活動膀胱治療市場における主要企業の市場ランキングと戦略に関する詳細な評価。

ページTOPに戻る

目次

1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 29
1.3.1 MARKETS COVERED 29
1.3.2 YEARS CONSIDERED 30
1.4 CURRENCY 30
1.5 LIMITATIONS 30
1.6 STAKEHOLDERS 31
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH APPROACH 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 PRIMARY RESEARCH 34
FIGURE 2 OVERACTIVE BLADDER TREATMENT MARKET: PRIMARY RESPONDENTS 34
2.1.2 TOP-DOWN AND BOTTOM-UP APPROACHES 35
FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE-BASED ESTIMATION 36
2.2 DATA TRIANGULATION APPROACH 37
FIGURE 5 DATA TRIANGULATION METHODOLOGY 37
2.2.1 SECONDARY RESEARCH 37
2.2.2 COVID-19-SPECIFIC ASSUMPTIONS 38
2.3 RESEARCH LIMITATIONS 39
2.4 RISK ASSESSMENT 39
2.5 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 39
2.5.1 SUPPLY SIDE 39
2.5.2 DEMAND SIDE 40
2.5.2.1 Insights from primary experts 40
3 EXECUTIVE SUMMARY 41
FIGURE 6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 41
FIGURE 7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE
2022 VS. 2027 (USD MILLION) 42
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE OVERACTIVE
BLADDER TREATMENT MARKET 43
 
4 PREMIUM INSIGHTS 44
4.1 OVERACTIVE BLADDER TREATMENT MARKET OVERVIEW 44
FIGURE 9 RISING PREVALENCE OF OVERACTIVE BLADDER SYNDROME AND FAVORABLE REIMBURSEMENT POLICIES ARE KEY FACTORS DRIVING MARKET GROWTH 44
4.2 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY TYPE AND COUNTRY (2021) 45
FIGURE 10 MIRABEGRON ACCOUNTED FOR THE LARGEST SHARE OF
THE ASIA PACIFIC MARKET IN 2021 45
4.3 OVERACTIVE BLADDER TREATMENT MARKET SHARE, BY DISEASE TYPE, 2022 VS. 2027 46
FIGURE 11 IDIOPATHIC OVERACTIVE BLADDER SYNDROME SEGMENT WILL
CONTINUE TO DOMINATE THE MARKET IN 2027 46
4.4 OVERACTIVE BLADDER TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 12 US TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 49
FIGURE 13 OVERACTIVE BLADDER TREATMENT MARKET: DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 49
TABLE 1 OVERACTIVE BLADDER TREATMENT MARKET: IMPACT ANALYSIS 49
5.2.1 MARKET DRIVERS 50
5.2.1.1 Rising prevalence of overactive bladder syndrome 50
5.2.1.2 Rapidly aging population and subsequent rise in incidence of diseases characterized by OAB 50
FIGURE 14 PROJECTED GROWTH IN THE ELDERLY POPULATION ABOVE 60,
2015 VS. 2030 VS. 2050 51
5.2.1.3 Development and use of innovative intravesical therapies 52
5.2.1.4 Growing R&D investments and the launch of novel therapies
in the coming years 52
5.2.2 MARKET RESTRAINTS 53
5.2.2.1 Frequent product recalls 53
5.2.2.2 Increased side effects of anticholinergic drugs 53
5.2.3 MARKET OPPORTUNITIES 53
5.2.3.1 Novel treatments, robust pipelines, and patent cliff of certain drugs 53
5.2.4 MARKET CHALLENGES 54
5.2.4.1 Social stigma and lack of awareness about OAB 54
5.3 IMPACT OF UNCERTAINTIES ON THE OVERACTIVE BLADDER TREATMENT MARKET 55
FIGURE 15 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE OVERACTIVE BLADDER TREATMENT MARKET 55
5.4 IMPACT OF COVID-19 ON THE OVERACTIVE BLADDER TREATMENT MARKET 56
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 56
FIGURE 16 REVENUE SHIFT AND NEW POCKETS FOR THE OVERACTIVE BLADDER TREATMENT MARKET 56
 
5.6 VALUE CHAIN ANALYSIS 57
FIGURE 17 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE 57
5.7 SUPPLY CHAIN ANALYSIS 58
FIGURE 18 DIRECT DISTRIBUTION—THE PREFERRED STRATEGY OF
PROMINENT COMPANIES 58
5.8 ECOSYSTEM ANALYSIS 59
FIGURE 19 ECOSYSTEM ANALYSIS OF THE PHARMACEUTICAL INDUSTRY 59
FIGURE 20 ECOSYSTEM ANALYSIS OF THE UROLOGY DEVICES INDUSTRY 60
5.9 REGULATORY SCENARIO 60
5.9.1 PHARMACEUTICAL INDUSTRY 60
5.9.1.1 Regulatory requirements 61
5.9.1.1.1 EU regulations 61
5.9.1.1.2 US regulations 61
5.9.2 MEDICAL DEVICE INDUSTRY 61
5.9.2.1 Regulatory requirements 62
5.9.2.1.1 EU regulations 62
5.9.2.1.2 US regulations 62
TABLE 2 LIST OF REGULATORY AUTHORITIES 63
5.10 TECHNOLOGY ANALYSIS 64
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 64
TABLE 3 OVERACTIVE BLADDER TREATMENT MARKET: LIST OF
CONFERENCES AND EVENTS 64
5.12 PATENT ANALYSIS 65
FIGURE 21 LIST OF MAJOR PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET 65
TABLE 4 OVERVIEW OF PATENTS IN THE OVERACTIVE BLADDER TREATMENT MARKET 66
5.13 PORTER’S FIVE FORCES ANALYSIS 67
TABLE 5 OVERACTIVE BLADDER TREATMENT MARKET:
PORTER’S FIVE FORCES ANALYSIS 67
5.13.1 THREAT FROM NEW ENTRANTS 67
5.13.2 THREAT FROM SUBSTITUTES 67
5.13.3 BARGAINING POWER OF BUYERS 67
5.13.4 BARGAINING POWER OF SUPPLIERS 68
5.13.5 DEGREE OF COMPETITION 68
5.14 PRICING ANALYSIS 68
TABLE 6 COST OF DRUGS USED IN OVERACTIVE BLADDER TREATMENT
IN VARIOUS REGIONS (GENERICS) 68
TABLE 7 COST OF BOTOX AND NEUROMODULATION USED IN OVERACTIVE
BLADDER TREATMENT IN VARIOUS REGIONS 68
TABLE 8 COST OF BRANDED DRUGS USED IN OVERACTIVE BLADDER
TREATMENT IN VARIOUS REGIONS 69
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 69
FIGURE 22 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND THEIR INFLUENCE ON THE BUYING PROCESS 69
FIGURE 23 KEY BUYING CRITERIA FOR OVERACTIVE BLADDER TREATMENT PRODUCTS AMONG END USERS 70
5.16 PIPELINE ANALYSIS 70
FIGURE 24 PIPELINE ANALYSIS: PHASES OF DRUGS IN CLINICAL TRIALS 70
6 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE 71
6.1 INTRODUCTION 72
TABLE 9 OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 72
TABLE 10 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 72
6.2 MIRABEGRON 73
6.2.1 FEWER SIDE EFFECTS COMPARED WITH ANTICHOLINERGICS ARE LIKELY TO PROPEL THE GROWTH OF THIS MARKET SEGMENT 73
TABLE 11 OVERACTIVE BLADDER TREATMENT MARKET FOR MIRABEGRON, BY REGION, 2020–2027 (USD MILLION) 73
6.3 ANTICHOLINERGICS 74
TABLE 12 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY REGION, 2020–2027 (USD MILLION) 74
TABLE 13 OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION) 75
6.3.1 SOLIFENACIN 75
6.3.1.1 Solifenacin is more effective than other anticholinergics in reducing the frequency of incontinence—a key factor driving market growth 75
TABLE 14 OVERACTIVE BLADDER TREATMENT MARKET FOR SOLIFENACIN,
BY REGION, 2020–2027 (USD MILLION) 76
6.3.2 OXYBUTYNIN 76
6.3.2.1 Oxybutynin is the most widely prescribed anticholinergic drug in the OAB market 76
TABLE 15 OVERACTIVE BLADDER TREATMENT MARKET FOR OXYBUTYNIN,
BY REGION, 2020–2027 (USD MILLION) 77
6.3.3 FESOTERODINE 77
6.3.3.1 Fesoterodine exhibits antimuscarinic effects on the muscarinic acetylcholine receptors in the detrusor muscle, leading to a decrease in bladder contractions 77
TABLE 16 OVERACTIVE BLADDER TREATMENT MARKET FOR FESOTERODINE,
BY REGION, 2020–2027 (USD MILLION) 78
6.3.4 DARIFENACIN 78
6.3.4.1 Cost of darifenacin is higher than other anticholinergics, which is likely to restrain market growth to a certain extent 78
TABLE 17 OVERACTIVE BLADDER TREATMENT MARKET FOR DARIFENACIN,
BY REGION, 2020–2027 (USD MILLION) 79
6.3.5 TOLTERODINE 79
6.3.5.1 Tolterodine is the third-most-prescribed drug for OAB as it has fewer side effects and offers long-term clinical efficacy 79
TABLE 18 OVERACTIVE BLADDER TREATMENT MARKET FOR TOLTERODINE, BY REGION, 2020–2027 (USD MILLION) 80
 
6.3.6 TROSPIUM 80
6.3.6.1 Trospium is associated with a lower incidence of dry mouth, as a result of which its discontinuation rate is relatively low 80
TABLE 19 OVERACTIVE BLADDER TREATMENT MARKET FOR TROSPIUM,
BY REGION, 2020–2027 (USD MILLION) 81
6.3.7 OTHER ANTICHOLINERGICS 81
TABLE 20 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER ANTICHOLINERGICS, BY REGION, 2020–2027 (USD MILLION) 81
6.4 BOTOX 82
6.4.1 HIGHER EFFICACY OF BOTOX THAN ANTICHOLINERGICS MAKES IT A POPULAR TREATMENT ALTERNATIVE 82
TABLE 21 OVERACTIVE BLADDER TREATMENT MARKET FOR BOTOX, BY REGION,
2020–2027 (USD MILLION) 82
6.5 NEUROMODULATION 83
6.5.1 INCREASING ADOPTION OF NEUROMODULATION FOR OVERACTIVE BLADDER TREATMENT TO DRIVE GROWTH IN THIS MARKET SEGMENT 83
TABLE 22 OVERACTIVE BLADDER TREATMENT MARKET FOR NEUROMODULATION,
BY REGION, 2020–2027 (USD MILLION) 83
6.6 OTHER TREATMENTS 84
TABLE 23 OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER TREATMENTS,
BY REGION, 2020–2027 (USD MILLION) 84
7 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE 85
7.1 INTRODUCTION 86
TABLE 24 OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 86
7.2 IDIOPATHIC OVERACTIVE BLADDER SYNDROME 87
7.2.1 AVAILABILITY OF REIMBURSEMENTS FOR DRUGS USED TO TREAT IDIOPATHIC OAB TO FUEL GROWTH IN THIS MARKET 87
TABLE 25 IDIOPATHIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 87
7.3 NEUROGENIC OVERACTIVE BLADDER SYNDROME 88
TABLE 26 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 27 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 89
7.3.1 PARKINSON'S DISEASE 89
7.3.1.1 Increased use of anticholinergics and beta-adrenergic agonists for the treatment of Parkinson’s disease to drive market growth 89
TABLE 28 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR PARKINSON’S DISEASE, BY REGION, 2020–2027 (USD MILLION) 90
7.3.2 STROKES 90
7.3.2.1 Rising prevalence of strokes to increase the incidence of OAB and fuel the demand for OAB treatment 90
TABLE 29 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR STROKES,
BY REGION, 2020–2027 (USD MILLION) 91
7.3.3 MULTIPLE SCLEROSIS 91
7.3.3.1 Favorable reimbursement policies to support the growth of the
OAB treatment market for MS 91
TABLE 30 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR MULTIPLE SCLEROSIS, BY REGION, 2020–2027 (USD MILLION) 92
7.3.4 SPINAL CORD INJURIES 92
7.3.4.1 High prevalence of bladder overactivity in SCI contributes to the growth of the neurogenic bladder overactivity treatment market 92
TABLE 31 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR SPINAL CORD INJURIES, BY REGION, 2020–2027 (USD MILLION) 93
7.3.5 OTHER DISORDERS 93
TABLE 32 NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET FOR OTHER DISORDERS, BY REGION, 2020–2027 (USD MILLION) 94
8 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION 95
8.1 INTRODUCTION 96
TABLE 33 OVERACTIVE BLADDER TREATMENT MARKET, BY REGION,
2020–2027 (USD MILLION) 96
8.2 NORTH AMERICA 96
FIGURE 25 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT 97
TABLE 34 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 35 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 36 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 98
TABLE 37 NORTH AMERICA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 99
TABLE 38 NORTH AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 99
8.2.1 US 99
8.2.1.1 Favorable reimbursement policies make the US the largest market for bladder overactivity treatment 99
TABLE 39 US: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 100
TABLE 40 US: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION) 101
TABLE 41 US: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 101
TABLE 42 US: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 102
8.2.2 CANADA 102
8.2.2.1 Increased use of and demand for BOTOX to treat overactive bladder to drive market growth in Canada 102
TABLE 43 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 103
TABLE 44 CANADA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 45 CANADA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 104
TABLE 46 CANADA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 104
8.3 EUROPE 104
TABLE 47 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 48 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 105
TABLE 49 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 106
TABLE 50 EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 106
TABLE 51 EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 107
8.3.1 GERMANY 107
8.3.1.1 Aging population and a high prevalence of OAB, especially in women, are expected to increase target patient groups in Germany 107
TABLE 52 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 108
TABLE 53 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 54 GERMANY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 109
TABLE 55 GERMANY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 109
8.3.2 UK 109
8.3.2.1 Initiatives and awareness campaigns in the UK to drive growth
in the OAB market 109
TABLE 56 ANNUAL COST OF OVERACTIVE BLADDER TREATMENT IN THE UK 110
TABLE 57 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 111
TABLE 58 UK: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS,
BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 59 UK: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 112
TABLE 60 UK: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 112
8.3.3 FRANCE 112
8.3.3.1 Low reimbursement rate in France compared to other countries may limit market growth to a certain extent 112
TABLE 61 REIMBURSEMENT RATES FOR OVERACTIVE BLADDER TREATMENT IN FRANCE 113
TABLE 62 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 113
TABLE 63 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 64 FRANCE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 114
TABLE 65 FRANCE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 115
8.3.4 ITALY 115
8.3.4.1 Italian pharmaceutical industry is expected to offer lucrative growth opportunities to OAB drug manufacturers 115
TABLE 66 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 67 ITALY: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 68 ITALY: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE,
2020–2027 (USD MILLION) 117
TABLE 69 ITALY: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 117
8.3.5 SPAIN 117
8.3.5.1 Changing demographics and high OAB prevalence in Spain offer significant growth opportunities for the bladder overactivity treatment market 117
TABLE 70 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 118
TABLE 71 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 72 SPAIN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 119
TABLE 73 SPAIN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 120
8.3.6 REST OF EUROPE 120
TABLE 74 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 75 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 76 REST OF EUROPE: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 121
TABLE 77 REST OF EUROPE: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
8.4 ASIA PACIFIC 122
FIGURE 26 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET SNAPSHOT 123
TABLE 78 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 79 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 124
TABLE 80 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 81 ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 125
TABLE 82 ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 126
8.4.1 JAPAN 126
8.4.1.1 Advancements in treatment options to fuel growth
in the market in Japan 126
TABLE 83 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 84 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 85 JAPAN: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 128
TABLE 86 JAPAN: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 128
8.4.2 CHINA 128
8.4.2.1 Growing adoption of BOTOX for OAB treatment makes China a lucrative market 128
TABLE 87 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 129
TABLE 88 CHINA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 89 CHINA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 130
TABLE 90 CHINA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 131
8.4.3 INDIA 131
8.4.3.1 India is the world’s largest producer of generic drugs— a key factor driving market growth 131
TABLE 91 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 132
TABLE 92 INDIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 93 INDIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 133
TABLE 94 INDIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 133
8.4.4 AUSTRALIA 133
8.4.4.1 Growing aging population is likely to increase the number of patients suffering from OAB in Australia—a major factor supporting the growth of this market 133
TABLE 95 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 96 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 97 AUSTRALIA: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 135
TABLE 98 AUSTRALIA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 135
8.4.5 REST OF ASIA PACIFIC 135
TABLE 99 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 100 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 101 REST OF ASIA PACIFIC: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 137
TABLE 102 REST OF ASIA PACIFIC: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
8.5 LATIN AMERICA 138
TABLE 103 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 104 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 105 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 106 LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 139
TABLE 107 LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
8.5.1 BRAZIL 140
8.5.1.1 Increased use of overactive bladder drugs in the country to
drive growth in the market 140
FIGURE 27 DISTRIBUTION OF POPULATION IN BRAZIL (ABOVE-60 AGE GROUP),
2004–2050 140
TABLE 108 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 110 BRAZIL: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 142
TABLE 111 BRAZIL: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 142
8.5.2 MEXICO 142
8.5.2.1 Rising prevalence of OAB to drive growth in the market in Mexico 142
TABLE 112 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE,
2020–2027 (USD MILLION) 143
TABLE 113 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 114 MEXICO: OVERACTIVE BLADDER TREATMENT MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION) 144
TABLE 115 MEXICO: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 144
8.5.3 REST OF LATIN AMERICA 145
TABLE 116 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 118 REST OF LATIN AMERICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 146
TABLE 119 REST OF LATIN AMERICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 146
 
8.6 MIDDLE EAST & AFRICA 146
8.6.1 RISING AWARENESS OF OAB IS LIKELY TO DRIVE THE GROWTH OF THE MARKET IN THE MIDDLE EAST & AFRICA 146
TABLE 120 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 121 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET FOR ANTICHOLINERGICS, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 122 MIDDLE EAST & AFRICA: OVERACTIVE BLADDER TREATMENT MARKET,
BY DISEASE TYPE, 2020–2027 (USD MILLION) 148
TABLE 123 MIDDLE EAST & AFRICA: NEUROGENIC OVERACTIVE BLADDER TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 148
9 COMPETITIVE LANDSCAPE 149
9.1 INTRODUCTION 149
9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 149
FIGURE 28 OVERACTIVE BLADDER TREATMENT MARKET: STRATEGIES ADOPTED
BY KEY PLAYERS 149
9.3 MARKET SHARE ANALYSIS 150
FIGURE 29 OVERACTIVE BLADDER TREATMENT MARKET: MARKET
SHARE ANALYSIS OF KEY PLAYERS (2021) 150
TABLE 124 OVERACTIVE BLADDER TREATMENT MARKET: DEGREE OF COMPETITION 150
9.4 REVENUE ANALYSIS 152
FIGURE 30 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 152
9.5 COMPANY EVALUATION QUADRANT 152
9.5.1 STARS 153
9.5.2 EMERGING LEADERS 153
9.5.3 PERVASIVE PLAYERS 153
9.5.4 PARTICIPANTS 153
FIGURE 31 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX, 2021 154
9.6 COMPETITIVE BENCHMARKING OF TOP 20 PLAYERS 155
9.6.1 COMPANY FOOTPRINT (20 COMPANIES) 155
TABLE 125 COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET 155
9.6.2 COMPANY PRODUCT FOOTPRINT (20 COMPANIES) 156
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN
THE OVERACTIVE BLADDER TREATMENT MARKET 156
9.6.3 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 157
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
IN THE OVERACTIVE BLADDER TREATMENT MARKET 157
9.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 158
9.7.1 PROGRESSIVE COMPANIES 158
9.7.2 STARTING BLOCKS 158
9.7.3 RESPONSIVE COMPANIES 158
9.7.4 DYNAMIC COMPANIES 158
FIGURE 32 OVERACTIVE BLADDER TREATMENT MARKET:
COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021 159
9.7.5 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 160
TABLE 128 OVERACTIVE BLADDER TREATMENT MARKET: DETAILED LIST OF
KEY START-UPS/SMES 160
TABLE 129 OVERACTIVE BLADDER TREATMENT MARKET:
COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES) 161
9.8 COMPETITIVE SCENARIO AND TRENDS 162
9.8.1 PRODUCT LAUNCHES & APPROVALS 162
TABLE 130 PRODUCT LAUNCHES & APPROVALS, JANUARY 2019–MAY 2022 162
9.8.2 DEALS 162
TABLE 131 DEALS, JANUARY 2019–MAY 2022 162
10 COMPANY PROFILES 163
10.1 KEY PLAYERS 163
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 ASTELLAS PHARMA INC. 163
TABLE 132 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW 163
FIGURE 33 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2021) 164
10.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 166
TABLE 133 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW 166
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 166
10.1.3 PFIZER INC. 168
TABLE 134 PFIZER INC.: BUSINESS OVERVIEW 168
FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2021) 169
10.1.4 ABBVIE INC. 171
TABLE 135 ABBVIE INC.: BUSINESS OVERVIEW 171
FIGURE 36 ABBVIE INC.: COMPANY SNAPSHOT (2021) 172
10.1.5 VIATRIS INC. 173
TABLE 136 VIATRIS INC.: BUSINESS OVERVIEW 173
FIGURE 37 VIATRIS INC.: COMPANY SNAPSHOT (2021) 174
10.1.6 HISAMITSU PHARMACEUTICAL CO., INC. 175
TABLE 137 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW 175
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2020) 175
10.1.7 JOHNSON & JOHNSON SERVICES, INC. 176
TABLE 138 JOHNSON & JOHNSON SERVICES, INC.: BUSINESS OVERVIEW 176
FIGURE 39 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2021) 176
10.1.8 ENDO PHARMACEUTICALS INC. 178
TABLE 139 ENDO PHARMACEUTICALS INC.: BUSINESS OVERVIEW 178
FIGURE 40 ENDO PHARMACEUTICALS INC.: COMPANY SNAPSHOT 178
10.1.9 LUPIN 179
TABLE 140 LUPIN: BUSINESS OVERVIEW 179
FIGURE 41 LUPIN: COMPANY SNAPSHOT (2021) 179
10.1.10 AMNEAL PHARMACEUTICALS LLC 180
TABLE 141 AMNEAL PHARMACEUTICALS LLC: BUSINESS OVERVIEW 180
FIGURE 42 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2021) 180
10.1.11 SUN PHARMACEUTICAL INDUSTRIES LTD. 182
TABLE 142 SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW 182
FIGURE 43 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 183
10.1.12 GLENMARK 184
TABLE 143 GLENMARK: BUSINESS OVERVIEW 184
FIGURE 44 GLENMARK: COMPANY SNAPSHOT (2021) 184
10.1.13 MACLEODS PHARMACEUTICALS LTD. 186
TABLE 144 MACLEODS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW 186
FIGURE 45 MACLEODS PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021) 186
10.1.14 MEDTRONIC 187
TABLE 145 MEDTRONIC: BUSINESS OVERVIEW 187
FIGURE 46 MEDTRONIC: COMPANY SNAPSHOT (2021) 188
10.1.15 AJANTA PHARMA 190
TABLE 146 AJANTA PHARMA: BUSINESS OVERVIEW 190
FIGURE 47 AJANTA PHARMA: COMPANY SNAPSHOT (2021) 191
10.1.16 GRANULES INDIA LIMITED 192
TABLE 147 GRANULES INDIA LIMITED: BUSINESS OVERVIEW 192
FIGURE 48 GRANULES INDIA LIMITED: COMPANY SNAPSHOT (2021) 192
10.2 OTHER PLAYERS 194
10.2.1 UROVANT SCIENCES 194
TABLE 148 UROVANT SCIENCES: BUSINESS OVERVIEW 194
10.2.2 APOTEX INC. 195
TABLE 149 APOTEX INC.: BUSINESS OVERVIEW 195
10.2.3 LABORIE 196
TABLE 150 LABORIE: BUSINESS OVERVIEW 196
10.2.4 INTAS PHARMACEUTICALS LTD. 197
TABLE 151 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW 197
10.2.5 BAYER AG 198
TABLE 152 BAYER AG: BUSINESS OVERVIEW 198
10.2.6 MEDYTOX 199
TABLE 153 MEDYTOX: BUSINESS OVERVIEW 199
10.2.7 ALTHERX PHARMACEUTICALS 200
TABLE 154 ALTHERX PHARMACEUTICALS: BUSINESS OVERVIEW 200
10.2.8 TAIHO PHARMACEUTICAL CO., LTD. 201
TABLE 155 TAIHO PHARMACEUTICAL CO., LTD.: BUSINESS OVERVIEW 201
10.2.9 HUGEL, INC. 202
TABLE 156 HUGEL, INC.: BUSINESS OVERVIEW 202
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 203
11.1 DISCUSSION GUIDE 203
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 206
11.3 AVAILABLE CUSTOMIZATIONS 208
11.4 RELATED REPORTS 208
11.5 AUTHOR DETAILS 209